The Total Thrombus-formation Analyser System (T-TAS) is a whole blood flow chamber system for the measurement of in vitro thrombus formation under variable shear stress conditions. Our current study sought to evaluate the potential utility of the T-TAS for the measurement of thrombus formation within human and mouse whole blood. T-TAS microchips (collagen, PL chip; collagen/tissue thromboplastin, AR chip) were used to analyse platelet or fibrin-rich thrombus formation respectively. Blood samples from humans (healthy and patients with mild bleeding disorders) and wild-type (WT), mice were tested. Light transmission lumiaggregometer (lumi-LTA) was performed in PRP using several concentrations of ADP, adrenaline, arachidonic acid, collagen, PAR-1 peptide and ristocetin. Thrombus growth (N=22)
Abstract
The Total Thrombus-formation Analyser System (T-TAS) is a whole blood flow chamber system for the measurement of in vitro thrombus formation under variable shear stress conditions. Our current study sought to evaluate the potential utility of the T-TAS for the measurement of thrombus formation within human and mouse whole blood. T-TAS microchips (collagen, PL chip; collagen/tissue thromboplastin, AR chip) were used to analyse platelet or fibrin-rich thrombus formation respectively. Blood samples from humans (healthy and patients with mild bleeding disorders) and wild-type (WT), mice were tested. Light transmission lumiaggregometer (lumi-LTA) was performed in PRP using several concentrations of ADP, 55.4 and 301±66.2 respectively). In contrast, no differences in the AUC between 240s -1 and 600s -1 were observed in the AR chip (1593±122 and 1591±158). The intra-assay coefficient of variation (CV) (n=10) in the PL chip (1000s -1 ) and AR chip (240s -1 ) were T1014.1%, T6016.7%, T10-6022.8% and AUC1024.4% or T10 9.03%, T808.64%, T10-8023.8% and AUC305.1%. AR chip thrombus formation was inhibited by rivaroxaban (1µM), but not with ticagrelor (10µM). In contrast, PL chip thrombus formation was totally inhibited by ticagrelor. T-TAS shows an overall agreement with lumi-LTA in 87% of patients (n=30) with normal platelet counts recruited into the genotyping and phenotyping of platelet (GAPP) study and suspected to have a platelet function defect. The onset (T10) of thrombus formation in WT mice (N= 4) was shorter when compared to humans e.g. PL chip (1000s -1 ) T10 were 02:02±00:23 and 03:30±0:45 respectively). T-TAS measures in vitro thrombus formation and can be used for monitoring
Introduction
Haemostasis is an important process that maintains the integrity of the circulatory system and minimises blood loss upon vascular damage. When a blood vessel-wall is injured a number of concomitant events occur. Initially, circulating platelets are recruited to the site of injury, where they are activated to become a platelet plug. Simultaneously blood coagulation is triggered by tissue factor resulting in thrombin generation and fibrin formation. The formation of fibrin, together with the platelet plug become major components of the developing thrombus at the sight of injury to prevent bleeding [1] .
A number of instruments have now become available to investigate bleeding disorders by accessing platelet function defects. However, the most common used techniques such LTA are aggregation based and so do not access platelet in their physiological condition. The more recent developed methods such as the impact cone and plate(let) analyser (CPA), PFA-200 and the Total Thrombus-formation Analysis System (T-TAS) are flow based methods using whole blood and therefore measure platelet function under more physiological conditions. Although both systems measure thrombus formation under high shear, CPA monitors platelet adhesion to a polystyrene plate and the PFA-200 measures thrombus formation within a small aperture [2] . Therefore, both are sensitive to VWF levels [3] . In contrast, the T-TAS has the advantage of evaluating thrombus formation in more physiological and variable flow conditions with varying effects of VWF levels [4] .
The T-TAS device is provided with two types of disposable ready-to-use microchips: (1) a platelet (PL) chip coated with collagen for assessing platelet thrombus formation and (2) an atherome (AR) chip coated with collagen and tissue factor for assessing white thrombus formation mediated by the activation of coagulation and platelets. The device therefore offers a potential advantage of simultaneous assessment of both platelet and coagulation defects [5, 6] .
The T-TAS was initially designed to monitor the effectiveness of antithrombotic agents. A number of studies have reported its potential utility in assessment of anti-platelet drugs e.g.
aspirin, clopidogrel, PAR-1 and PAR-4 antagonists [6] [7] [8] and anti-thrombotic agents e.g. direct thrombin and factor Xa inhibitors [9] . T-TAS has also demonstrated high sensitivity in detecting coagulation disorders such as haemophilia [10] and von Willebrand disease [11] , as well as platelet function defects for example, storage pool disease (SPD) [12] . In assessing acquired haemorrhagic conditions, the T-TAS was able to predict the risk of bleeding in atrial fibrillation patients undergoing catheter ablation [13] . Furthermore, T-TAS has been demonstrated to be a useful tool in the study of thrombus formation in blood taken from animal models such as miniature pigs [14] and mice [10, 15] .
Materials and Methods

Participants
A total of 59 individuals (37 patients and 22 controls) were evaluated and recruited into the GAPP study (www.birmingham.ac.uk/plateletgapp) from 9 UK Haemophilia comprehensive care centres. All patients or their parents gave written informed consent in accordance with the GAPP project ethical approval (REC reference: 06/MRE07/36).
Reagents
ADP, ristocetin and adrenaline were purchased from Sigma (Poole, UK 
Platelet aggregation in platelet-rich plasma
Tests were carried out as described previously [16] . Aggregation studies were performed by using a dual Chrono-log lumiaggregometer (model ChronoLog 460 VS aggregometer, LabMedics, UK) in 400 L mini cuvettes and stirred at 1200 rpm at 37°C. The 100% line was set using autologous PPP and the 0% baseline established with native undiluted PRP. After one min platelets were stimulated with ADP (10, 30, and 100 µM), adrenaline (10, 30, and 100 µM), arachidonic acid (0.5, 1, and 1.5 mM), U46619 (1 and 3 µM), collagen (1 and 3 µg/mL), collagen related peptide CRP (1, 3, and 10 µg/mL), PAR-1 peptide (10, 30 and 100 µM), and ristocetin (1.5 and 2 mg/mL). Platelet aggregation was monitored by measuring the change in optical density over 5 min after addition of the agonists and the maximal percentage of aggregation was recorded. ATP secretion from platelet dense granules was assessed simultaneously by lumi-LTA using the luciferase reagent (Chronolume) as described previously [16] Evaluation of thrombus formation under flow conditions on human blood
In vitro thrombus formation was analysed on the T-TAS instrument (Zacros, Fujimori Kogyo
Co. Ltd., Tokyo, Japan) using two types of microchips, the PL chip (width 40 m × depth 40 m) (containing 25 capillary channels coated with type 1 collagen) and the AR chip (width 300 µm, depth 60 or 120 µm, length 15 mm) (consisting of a single capillary channel coated with collagen and thromboplastin). The PL chip was used to analyse platelet thrombus formation (PTF) under three different shear rates (1000, 1500 and 2000s -1 ). Briefly, hirudin anticoagulated whole blood (320 µL) was pipetted in the reservoir then perfused at 37°C through the PL chip by a pneumatic pump. After the perfusion of blood was initiated, platelets were then activated by the collagen coated on the capillary. The AR chip was used to analyse white thrombus formation (WTF) under two different shear rates (240s -1 and 600s -1 ). Briefly, citrated whole blood (480 µl) was re-calcified by mixing with 20 µl of 0.3 M CaCTI immediately before it was pipetted in the reservoir. The re-calcified blood was then perfused at 37°C through the AR chip by the pneumatic pump. After the perfusion of blood through the capillary was initiated, platelets and the extrinsic coagulation pathway were simultaneously activated by collagen and tissue thromboplastin. To prevent the outlet port from clotting, the blood is mixed with 25 mM EDTA (pH 10.5). The process of thrombus formation in both chips was monitored by flow pressure changes in the capillary using the pressure sensor located between the pump and the reservoir. As thrombus formation proceeded on the coated surface, the capillary is gradually for 10/30 min after the start of assay for the PL and AR chips respectively. AUC is used to quantify a decrease in WTF when OT is not achieved during the time period of assay.
Antithrombotic effects of ticagrelor and rivaroxaban under flow conditions
Ticagrelor (final concentration, 10 µM) was incubated either in hirudin or citrate anticoagulated blood for 10 min at room temperature. Rivaroxaban (final concentration, 1 µM) was incubated in citrate anticoagulated blood for 3-5 min at room temperature. After incubation blood were perfused through either the PL chip and/or AR chip within the T-TAS instrument as described above.
Statistical analysis
All control results were run on Graph Pad Prism version 7.0 software to demonstrate the normal distribution and to obtain the median and standard deviation values which were then used to determine the cut-off values. Abnormal results by lumi-LTA were determined based on our previously published methodology that is based upon both the magnitude and time course of response [16, 17] . The time course, including reversibility is of particular importance. In contrast, abnormal thrombus formation by T-TAS was determined based on the cut off values of AUC10 and the T10 parameters calculated as the 5 th percentile from healthy controls.
Results
Measurement of T-TAS in healthy subjects
22 healthy subjects (10 males and 12 females; median age 31 ± 7 years) were investigated.
Overall, the T-TAS shows some variation in thrombus formation among healthy subjects on Intra-assay coefficients of variation (CV) were calculated from 10 sequential measurements of a single sample obtained from one healthy subject (Table 1) . Overall, the difference of CV between shear rates within the PL chip was more significant compared to the AR chip. On PL chip the CVs of T60, T10-60 and AUC10 were smaller at 2000 s − 1 than at 1000/1500 s − 1 whereas the CVs of T10 were almost identical at all three shear rates. In AR chip however, the CV of all four parameters were low at 600 s − 1 than that at 240 s − 1 ( Table 1) .
Measurement of blood from healthy subjects spiked with antithrombotic drugs
No thrombus formation was observed in the PL chip when blood was pre-treated with ticagrelor (10 µM) ( Figure 1E ). In contrast, thrombus formation in the AR chip was not affected by addition of ticagrelor ( Figure 1F ). However, thrombus formation in the PL chip was observed with blood pre-treated with rivaroxaban (1µM) but varies between subjects when perfused through the AR chip at lower shear rates ( Figure 1G ).
Measurement of T-TAS on samples from patients recruited into the GAPP study with
suspected platelet function defects.
We analysed 30 patients (8 male and 22 female) with a median age 35 (range 7-73) recruited into the GAPP study and compared T-TAS (PL chip) results with lumi-LTA. All patients had normal platelet counts (261 ± 68 x10 9 /L). Of 30 patients tested ( Figure 2C ), 10 (33.3%) patients gave abnormal responses by lumi-LTA to one or more agonists as defined using previous criteria [17] . In contrast, 8 (27%) patients were detected to have abnormal thrombus formation by T-TAS, as defined using the cut off values obtained from healthy controls. T-TAS detected an abnormality in 1 patient that was normal by lumi-LTA, whereas 3 samples were normal by T-TAS but abnormal by lumi-LTA (Figure 2A and 2B, respectively) 
Analysis and identification of patients with platelet function defects
Functional defects identified by lumi-LTA were classified into 4 main groups (Gi defects, secretion defects, COX-like defect and multiple defects) according to their pattern of responses to specific agonists as previously described [17] . As shown in figure 2D , T-TAS detected all patients classified by lumi-LTA with COX-like defect or secretion defects (1 and 2 patients respectively). In contrast, T-TAS only detected 1/3 patients with Gi defects but 3 out of 4 with multiple defects.
Measurement of T-TAS in sample from GAPP patients with thrombocytopenia recruited with suspected platelet function defects
We additionally analysed 7 patients (2 male and 5 female) found to have mild to marked thrombocytopenia as characterized by low whole blood platelet counts (<150 x10 9 /L), but normal platelet counts in PRP when tested by lumi-LTA. The whole blood platelet counts (mean ± SD) were 77 ± 34 (x10 9 /L). The waveform of each individual patient is presented in figure 2A . AUC10 parameters ( Figure 2B ) showed significant differences between healthy controls (n=22) and patients (n=7). All 7 patients tested exhibited abnormal thrombus formation within the T-TAS (Figure 2A ). Interestingly, 4/7 patients were also detected by lumi-LTA to have platelet function defects (3 secretion and 1 Cox-like defects) in additional to their thrombocytopenia.
Measurement of T-TAS in samples from WT mice
Blood samples from WT (n=5) were tested using PL chips (1000 s The difference in thrombus formation between WT mice (n=5) and healthy humans (n=22) was then compared. Overall, thrombus formation in WT mice was more rapid on both the PL and AR chips ( Figure 3A ) than in humans. With PL chip measurements, the differences between two models were significant with all parameters. For example, WT mice values (median) at 1000 s -1 were T10 = 02:02, T60 = 04:40, T10-60 = 02:38 and AUC10 = 405.5 (table 3) whereas the values in humans (median) at the same shear were T10= 03:30, T60= 08:10, T10-60 = 04:40 and AUC10 = 260 (results not shown). In contrast, with AR chip measurements the different between two models were only significant with T10, T80 and AUC30 but not with T10-80 ( Figure   3C ).
Discussion
The T-TAS is a flow chamber system that evaluates thrombus formation using whole blood samples that flow on different thrombogenic surfaces under arterial or venous shear conditions. This approach offers an advantage for rapidly assessing thrombus formation in more physiological conditions using whole blood under flow. Furthermore, this method requires comparatively small blood volumes (350 l) making it potentially practical for clinical application [4] . Importantly, T-TAS has all the five requirements of flow assays methods as described by Roest et al. [18] . We therefore sought to evaluate the potential utility of the T-TAS for assessing thrombus formation in blood from healthy individuals, blood spiked with antithrombotic agents, blood from GAPP study patients with mild bleeding disorders and blood from mice.
In healthy controls, both the start and end points of thrombus formation varied among individuals within both chips suggesting that measurements obtained using the T-TAS may reflect individual variability of thrombus formation. Within the PL chip, the rate of thrombus formation was shorter at higher shear rates which was reflected in all parameters measured ( Figure 1B) . This supports the evidence that high-shear rates favour the GPIb-IX-V/VWF axis to induce more efficient thrombus formation [19] . In contrast, the effect of the shear rate within the AR chip was variable, in particular the onset (T10) ( Figure 1D) where the value at the high shear was greater than at the low shear in contrast to previous findings [4, 6] . However, an increased rate of thrombus growth (T10-80) in accordance with an increase in shear rate was observed on AR chip similar to that on PL chip, indicating that the shear rates accelerated the growth rate of the thrombus. Shear rate enhancement of T-TAS parameters were also reported by Hosokawa et al., and Yamaguchi et al., [4, 6] . In our study, the T-TAS also exhibited high intra-assay coefficients of variation (CV) within both chips (Table 1) . Typical CVs obtained were much higher than those described by Yamaguchi et al. although their sample size (n=5) was smaller [4] .
We also evaluated the utility of T-TAS in detecting the effect of antithrombotic therapy on haemostasis using two types of drugs. 1) The antiplatelet drug Ticagrelor (P2Y12 antagonist) and 2) The anticoagulant Rivaroxaban (factor Xa inhibitor). Ticagrelor (10 µM) completely suppressed thrombus formation within the PL chip. These findings agree with Hokosawa et al.
who also previously demonstrated that thrombus formation within the PL chip was inhibited by P2Y12 antagonists [5, 8] . In contrast, the inhibitory effect of Ticagrelor on thrombus formation was not observed within the AR chip. As thrombus formation within the AR at low shear rate is more dependent upon fibrin formation [6, 20] , it is possible that P2Y12 inhibitors are therefore expected to have no effect in this chip as platelets play little or no role in thrombus formation at low shear rates [7, 21] . Secondly, platelets within the AR chip could also be activated via the PAR-1 receptor by thrombin which is generated from activation of the coagulation pathways [21] . This was demonstrated by Hokosawa et al. by demonstrating that PAR-1 antagonism reduced thrombus formation within the AR chip [7] . In contrast, Rivaroxaban (1µM) incubation with whole blood within the AR chip displayed considerable variability on affecting thrombus formation with a delayed onset despite complete thrombus formation ( figure 1G ). Hokosawa et al. also demonstrated that Rivaroxaban (1µM) only moderately suppressed thrombus formation within the AR chip [9] . However, Sugihara et al.
demonstrated that Rivaroxaban at the estimated clinical peak dose (800 nM) significantly suppressed thrombus formation [22] . Furthermore, Hosokawa et al., also used T-TAS to show that the anticoagulant effect of thrombus formation was intensified when anticoagulant and antiplatelet drugs were used in combination [9] . These findings suggest that T-TAS could be a clinically useful tool for monitoring the antithrombotic effect on both platelet and coagulation pathways.
Furthermore, we performed a comparative evaluation of the T-TAS using the PL chip with GAPP patients with suspected platelet function defects and compared the results with the gold standard of lumi-LTA. Comparison of the overall results in 30 patients with normal platelet counts ( Table 2 ) demonstrated a good agreement between T-TAS (PL chip) and lumi-LTA with concordance in 87% of samples tested. As 67% of samples were defined as normal by lumi-LTA, T-TAS therefore gave a NPV of 86% suggesting that the test could be a potential screening tool for the characterisation of platelet function disorders. Interestingly, T-TAS also detected all patients with COX-like defects and secretion defects ( Figure 2D ). This finding is consistent with earlier reports showing that T-TAS was able to detect all patients diagnosed with SPD [12] . T-TAS also showed high consistency in detecting abnormalities in patients with multiple defects. This finding supports the earlier report suggesting that T-TAS is reliable in detecting more severe forms of platelet defects such Bernard-Soulier syndrome [12] . However, T-TAS failed to detect thrombus formation in all patients with thrombocytopenia including three patients that gave normal responses by lumi-LTA (Figure 2A and 2B ). This might suggest that T-TAS is not reliable for testing samples with low platelet counts and that thrombus formation is dependent on normal platelet numbers. An earlier study on healthy subjects demonstrated a good correlation between normal platelet counts and T-TAS parameters [4] .
Further studies are required to investigate the relationship between platelet counts and T-TAS parameters.
There is no single parameter that has been described to be more useful in defining haemostatic abnormalities within the T-TAS. Almost all studies evaluating bleeding disorders in the T-TAS have used AUC10/30 and to a lesser extent the T10 [11] [12] [13] 23] . AUC is particularly useful in quantifying a decrease in thrombus formation when occlusion time is not achieved during the time period of assay. In our study almost all samples (7/8) with abnormalities detected by T-TAS exhibited low values of AUC10. One patient however, gave normal values of AUC10 but with delayed T10 parameters. Interestingly, the patient was also found to have a defect by lumi-LTA. This might therefore suggest that a combination of T10 and AUC parameters are sufficient to identify any haemostatic abnormalities on T-TAS.
The use of comparatively small blood volumes for T-TAS makes it practical for studying exvivo thrombus formation in small animal models. This could potentially result in significant reduction of animal usage in research laboratories. To evaluate the utility of T-TAS for testing thrombus formation in mouse blood, we first analysed blood samples from WT mice. WT blood demonstrated more rapid total thrombus formation compared to human blood. Similar results were reported on studies of blood from miniature pigs [14] , suggesting that these animals might exhibit increased thrombogenicity than humans, possibly due to higher platelet counts ( Table   4) . As expected, all KO models displayed poor thrombus formation within the PL chip concurring with previous in vivo and in vitro findings [24] . In contrast, full thrombus formation was observed within the AR chip with all KO indicating that the coagulation pathways are normal and that platelets probably have little significant contribution to thrombus formation using this system, at a shear rate of 240 s −1 [23] .
Our present study has several limitations. Firstly, the study was performed with only a small group of patients suspected to have platelet function disorders. Therefore, for future studies it would be necessary to enrol a larger number of patients with known platelet function defects as well as other haemostatic abnormalities such as coagulation defects (e.g haemophilia and VWD). Secondly, the study of antithrombotic drugs was performed using a single concentration of either ticagrelor or rivaroxaban and were evaluated separately. It would be of interest in future studies to evaluate the T-TAS with a full range of antiplatelet drugs with different molecular targets and at different concentrations as well as in the combination with anticoagulant drugs. Lastly, the mouse models were only studied within the AR chip and at low shear rates. It would be of interest to determine if higher shear rates would also have detected similar platelet defects in these mice.
In summary, T-TAS has demonstrated a good agreement with Lumi-LTA suggesting that the technique could be applied to potentially screening patients with platelet function defects.
Moreover, the device might be a useful tool in monitoring antithrombotic therapy. Finally, we demonstrated that the T-TAS could provide valuable assistance in rapidly studying samples from animal models with the potential of reducing animal usage in research laboratories. Tables   Table 1 Intra-assay coefficients of variation (CV) in PL and AR chips measurements in a single sample obtained from a healthy control (n=10).
Table 2
Analysis of the agreement between the T-TAS and lumi-LTA in patient samples (n=30) displaying sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Table 3 T-TAS measurements in samples from WT mice (n=5) performed on both PL and AR chips using different shear rates. Data presented as mean and SD. 
